Flerie AB
FLERIE | ST
Overview
Corporate Details
- ISIN(s):
- SE0022447348
- LEI:
- 54930047C4A74IBXR037
- Country:
- Sweden
- Address:
- BERZELIUS VÄG 13, 171 65 Solna
- Website:
- https://www.flerie.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. Flerie was established in 2011 by Thomas Eldered, who co-founded and built one of the global top five drug manufacturers, Recipharm. Dr Carl-Johan Spak, now Senior Advisor, and Thomas laid the foundation for Flerie’s evergreen strategy and oversaw the early investments. Flerie sold Cormorant Pharmaceuticals to BMS in 2016 and Cobra Biologics to Cognate Bioservices in early 2020 – this enabled further investments. In 2018, Dr Ted Fjällman, then chief executive of one of the portfolio companies, joined as Venture Partner, later Partner and CEO of Flerie.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 15:30 |
Delisting Announcement
Bolagsverket har lämnat tillstånd att verkställa fusionsplanen mellan Flerie oc…
|
Swedish | 44.9 KB | |
| 2025-08-08 15:30 |
Delisting Announcement
The Swedish Companies Registration Office has granted permission to implement t…
|
English | 51.6 KB | |
| 2025-08-04 08:00 |
Net Asset Value
SUBSTANSVÄRDE – 31 juli 2025
|
Swedish | 43.5 KB | |
| 2025-08-04 08:00 |
Net Asset Value
NET ASSET VALUE – 31 July 2025
|
English | 43.0 KB | |
| 2025-07-31 09:00 |
Share Issue/Capital Change
Styrelsen i Flerie beslutar om inlösen av samtliga aktier av serie C inom ramen…
|
Swedish | 33.5 KB | |
| 2025-07-31 09:00 |
Share Issue/Capital Change
The Board of Directors of Flerie has resolved to redeem all Series C shares wit…
|
English | 42.1 KB | |
| 2025-07-31 08:00 |
Interim Report
|
Swedish | 1.3 MB | |
| 2025-07-31 08:00 |
Interim Report
|
English | 1.6 MB | |
| 2025-07-16 08:00 |
M&A Activity
Flerie AB:s dotterbolag Flerie Invest AB offentliggör slutligt utfall avseende …
|
Swedish | 49.2 KB | |
| 2025-07-16 08:00 |
M&A Activity
Flerie AB’s subsidiary Flerie Invest AB announces final outcome of the mandator…
|
English | 48.3 KB | |
| 2025-07-03 08:00 |
Net Asset Value
SUBSTANSVÄRDE – 30 juni 2025
|
Swedish | 43.5 KB | |
| 2025-07-03 08:00 |
Net Asset Value
NET ASSET VALUE – 30 June 2025
|
English | 43.1 KB | |
| 2025-07-01 08:00 |
Share Issue/Capital Change
Styrelsen i Flerie beslutar om omvandling av stamaktier till aktier av serie C …
|
Swedish | 42.3 KB | |
| 2025-07-01 08:00 |
Share Issue/Capital Change
The Board of Directors of Flerie has resolved to convert ordinary shares into S…
|
English | 42.3 KB | |
| 2025-06-16 10:00 |
M&A Activity
Flerie AB's subsidiary Flerie Invest AB publish the offer document for the mand…
|
English | 47.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Financière de Tubize S.A. | Belgium | TUBAT | |
|
Fine Foods & Pharmaceuticals Ntm | Italy | FF | |
|
Friulchem | Italy | FCM | |
|
FRP ADVISORY GROUP PLC | United Kingdom | FRP | |
|
Fuji Pharma Co.,Ltd. | Japan | 4554 | |
|
FunPep Company Limited | Japan | 4881 | |
|
Fuso Pharmaceutical Industries,Ltd. | Japan | 4538 | |
|
Galderma Group AG | Switzerland | GALD | |
|
GlaxoSmithKline PLC | United Kingdom | GSK | |
|
GNI Group Ltd. | Japan | 2160 |